Concomitant Use of Immunomodulators Affects the Durability of Infliximab Therapy in Children With Crohn’s Disease-Reference-Cited by-同舟云学术

Concomitant Use of Immunomodulators Affects the Durability of Infliximab Therapy in Children With Crohn’s Disease

Published:2015-10 Issue:10 Volume:13 Page:1748-1756
ISSN:1542-3565
Container-title:Clinical Gastroenterology and Hepatology
language:en
Short-container-title:Clinical Gastroenterology and Hepatology

Author:

Grossi Victoria,Lerer Trudy,Griffiths Anne,LeLeiko Neal,Cabrera Jose,Otley Anthony,Rick James,Mack David,Bousvaros Athos,Rosh Joel,Grossman Andrew,Saeed Shehzaad,Kay Marsha,Boyle Brendan,Oliva-Hemker Maria,Keljo David,Pfefferkorn Marian,Faubion William,Kappelman Michael D.,Sudel Boris,Markowitz James,Hyams Jeffrey S.

Publisher

Elsevier BV

Subject

Gastroenterology,Hepatology

Reference21 articles.

1. Induction and maintenance infliximab therapy for the treatment of moderate-to-severe Crohn's disease in children;Hyams;Gastroenterology,2007

2. Infliximab as first-line therapy in severe pediatric Crohn disease;de Ridder;J Pediatr Gastroenterol Nutr,2006

3. Infliximab maintains durable response and facilitates catch-up growth in luminal pediatric Crohn's disease;Church;Inflamm Bowel Dis,2014

4. A 10-year, single tertiary care center experience on the durability of infliximab in pediatric inflammatory bowel disease;Vahabnezhad;Inflamm Bowel Dis,2014

5. Increased effectiveness of early therapy with anti-tumor necrosis factor-alpha vs an immunomodulator in children with Crohn's disease;Walters;Gastroenterology,2014

Cited by 91 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Saudi consensus guidance for the diagnosis and management of inflammatory bowel disease in children and adolescents;Saudi Journal of Gastroenterology;2024-08-30

2. Clinical impacts of immunomodulator withdrawal from anti‐tumor necrosis factor combination therapy in pediatric inflammatory bowel disease;Journal of Pediatric Gastroenterology and Nutrition;2024-07

3. Comparison of Endoscopic Healing and Durability between Combination Therapy with Infliximab and Azathioprine versus Infliximab Monotherapy in Pediatric Crohn's disease;2024-06-25

4. Precise infliximab exposure and pharmacodynamic control to achieve deep remission in paediatric Crohn’s disease (REMODEL-CD): study protocol for a multicentre, open-label, pragmatic clinical trial in the USA;BMJ Open;2024-03

5. Comparison of endoscopic healing and durability between infliximab originator and CT-P13 in pediatric patients with inflammatory bowel disease;Frontiers in Immunology;2024-02-22